Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Accelerate Diagnostics Inc., Tucson, Arizona, USA.
J Clin Microbiol. 2019 Feb 27;57(3). doi: 10.1128/JCM.01711-18. Print 2019 Mar.
The Accelerate Pheno system (AXDX) is a rapid phenotypic bacterial identification and susceptibility testing system which is approved for use with positive blood cultures. is a nosocomial pathogen for which the limited treatment options include minocycline in the case of multidrug resistance. Here, we studied the performance of identification and minocycline susceptibility testing by AXDX using 101 contemporary sp. clinical isolates. Overall, the sensitivity for and complex identification was 100% (73/73) and 97.6% (82/84), respectively. Specificity for complex identification was 86.6% (13/15). The essential agreement of minocycline susceptibility results (±1 log MIC agreement) of AXDX MICs with reference broth microdilution was 98.0% (96/98). There were no very major errors or major errors. Overall, 24.5% (24/98) of results yielded minor errors. AXDX reliably identified and predicted minocycline susceptibility results, which should help guide treatment choices in a timely manner for infections where options are limited.
Accelerate Pheno 系统（AXDX）是一种快速表型细菌鉴定和药敏测试系统，已获准用于阳性血培养。 是一种医院获得性病原体，其治疗选择有限，包括多药耐药时使用米诺环素。在这里，我们使用 101 株当代 sp.临床分离株研究了 AXDX 对 的鉴定和米诺环素药敏测试的性能。总体而言， 鉴定和 复合鉴定的灵敏度分别为 100%（73/73）和 97.6%（82/84）。 复合鉴定的特异性为 86.6%（13/15）。AXDX MIC 与参考肉汤微量稀释法的米诺环素药敏结果（±1 log MIC 一致性）的基本一致性为 98.0%（96/98）。没有非常大的错误或主要错误。总体而言，24.5%（24/98）的结果存在次要误差。AXDX 可靠地鉴定了 并预测了米诺环素的药敏结果，这有助于及时指导治疗选择，对于选择有限的感染。
